EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lennox-Gastaut Syndrome: Clinical Advances and Multimodal Management

Aditi M Trivedi, Isabella Mateo, Ruhee Patel, Rajdeep Singh

Current Treatment Options in Neurology · 2026-12 · 28 (1)

DOI: 10.1007/s11940-026-00898-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Treatment Options in Neurology, online erschienen am 20.11.2026. Verfasst von Aditi M Trivedi und 3 weiteren Autor:innen. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wake Forest University.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose of Review This article presents a comprehensive review of the spectrum of treatments utilized for Lennox-Gastaut Syndrome (LGS) in children and adults, including pharmacologic, surgical, neuromodulatory and diet therapies. This review also discusses considerations of common comorbidities associated with LGS, as well as clinical trials exploring emerging new therapies. Recent Findings The therapeutic landscape of LGS is growing. There are currently 8 FDA approved anti-seizure medications (ASMs) indicated for the treatment of LGS, and several others are widely used off label. Several recent expert opinion consensus algorithms have been reported to guide the use of pharmacologic options. Additionally, neuromodulatory as well as diet therapies have been found to control seizures and in appropriately selected patients surgical options including disconnections such as corpus callosotomy procedures may be beneficial. Summary Lennox-Gastaut Syndrome (LGS) is a complex developmental and epileptic encephalopathy characterized by drug-resistant seizures, neurocognitive impairment, and distinct electrographic hallmarks. Given its refractory nature, treatment requires a structured, multimodal strategy that balances aggressive seizure reduction with comorbidity management. This involves appropriate trials with carefully chosen anti-seizure medications, and early evaluations for non-pharmacologic and surgical options especially when refractory. As patients transition into adulthood, management must adapt. Seizure patterns and electrographic features often evolve, requiring therapy individualized for seizure types such as sodium channel blockers for focal onset seizures. Furthermore, optimal care must extend beyond seizure frequency to address critical non-seizure comorbidities, including sleep disruption, psychiatric symptoms, and behavioral dysregulation. Finally, as genetic testing continues to uncover underlying etiologies, integrating emerging precision therapies targeting specific molecular pathways will be paramount to modifying the long-term neurodevelopmental trajectory of LGS.

Förderung

  • Wake Forest University

Zitieren

APA

Trivedi, A. M., Mateo, I., Patel, R., & Singh, R. (2026). Lennox-Gastaut Syndrome: Clinical Advances and Multimodal Management. Current Treatment Options in Neurology, 28(1). https://doi.org/10.1007/s11940-026-00898-2

Vancouver

Trivedi AM, Mateo I, Patel R, Singh R. Lennox-Gastaut Syndrome: Clinical Advances and Multimodal Management. Current Treatment Options in Neurology. 2026;28(1). doi:10.1007/s11940-026-00898-2

BibTeX
@article{Trivedi2026,
  author = {Trivedi, Aditi M and Mateo, Isabella and Patel, Ruhee and Singh, Rajdeep},
  title = {Lennox-Gastaut Syndrome: Clinical Advances and Multimodal Management},
  journal = {Current Treatment Options in Neurology},
  year = {2026},
  volume = {28},
  number = {1},
  doi = {10.1007/s11940-026-00898-2}
}
Kostenlos starten →